IDEAYA Q2 FY26 net loss widens to $112.45 million; revenue rises 35.02% to $8.86 million vs Q1 FY26

• IDEAYA Biosciences posted a net loss of $112.45 million, widening from $98.54 million in the prior quarter; loss per share deepened to $1.22 from $1.11.
• Collaboration revenue rose 35.02% from the prior quarter to $8.86 million; R&D expenses increased to $108.69 million from $95.73 million.
• Cash, cash equivalents, and marketable securities climbed to $1.24 billion at June 30 from $972.9 million at March 31, following $323.4 million in net offering proceeds.
• OptimUM-02 trial of darovasertib plus crizotinib in metastatic uveal melanoma met its primary endpoint; NDA filing is underway with completion expected in H2 2026.
• Management said the company is discussing an IDE849 Phase 3 registrational trial with the FDA, targeting initiation by end-2026; cash runway guidance into 2030 unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040600PR_NEWS_USPR_____SF18271) on August 04, 2026, and is solely responsible for the information contained therein.